Pharmacological interventions for prevention and management of delirium in intensive care patients:a systematic overview of reviews and meta-analyses by Barbateskovic, Marija et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Pharmacological interventions for prevention and management of delirium in intensive
care patients
Barbateskovic, Marija; Krauss, Sara Russo; Collet, Marie Oxenboell; Larsen, Laura Krone;
Jakobsen, Janus Christian; Perner, Anders; Wetterslev, Jørn
Published in:
BMJ Open
DOI:
10.1136/bmjopen-2018-024562
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Citation for published version (APA):
Barbateskovic, M., Krauss, S. R., Collet, M. O., Larsen, L. K., Jakobsen, J. C., Perner, A., & Wetterslev, J.
(2019). Pharmacological interventions for prevention and management of delirium in intensive care patients: a
systematic overview of reviews and meta-analyses. BMJ Open, 9, [e024562]. https://doi.org/10.1136/bmjopen-
2018-024562
Download date: 03. Feb. 2020
1Barbateskovic M, et al. BMJ Open 2019;9:e024562. doi:10.1136/bmjopen-2018-024562
Open access 
Pharmacological interventions for 
prevention and management of delirium 
in intensive care patients: a systematic 
overview of reviews and meta-analyses
Marija Barbateskovic,1,2 Sara Russo Krauss,1 Marie Oxenboell Collet,2,3 
Laura Krone Larsen,4 Janus Christian Jakobsen,1,2,5 Anders Perner,2,3 
Jørn Wetterslev1,2
To cite: Barbateskovic M, 
Krauss SR, Collet MO, et al.  
Pharmacological interventions 
for prevention and management 
of delirium in intensive 
care patients: a systematic 
overview of reviews and 
meta-analyses. BMJ Open 
2019;9:e024562. doi:10.1136/
bmjopen-2018-024562
 ► Prepublication history and 
additional material for this 
paper are available online. To 
view these files, please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2018- 
024562). 
Received 1 June 2018
Revised 7 September 2018
Accepted 7 December 2018
For numbered affiliations see 
end of article.
Correspondence to
Marija Barbateskovic;  
 marija. barbateskovic@ ctu. dk
Research
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY-NC. No 
commercial re-use. See rights 
and permissions. Published by 
BMJ.
AbstrACt
Objectives We assessed the evidence from reviews 
and meta-analyses of randomised clinical trials on the 
effects of pharmacological prevention and management of 
delirium in intensive care unit (ICU) patients.
Methods We searched for reviews in July 2017 in: 
Cochrane Library, MEDLINE, Embase, Science Citation 
Index, BIOSIS Previews, CINAHL and LILACS. We assessed 
whether reviews were systematic according to Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) and assessed the methodological 
quality using ROBIS. 
Outcome measures Primary outcomes: all-cause 
mortality, serious adverse events, prevention of delirium 
and management of delirium. Secondary outcomes: quality 
of life; non-serious adverse events and cognitive function.
results We included 378 reviews: 369 narrative reviews, 
eight semisystematic reviews which failed on a maximum 
of two arbitrary PRISMA criteria and one systematic 
review fulfilling all 27 PRISMA criteria. For the prevention 
of delirium, we identified the one systematic review and 
eight semisystematic reviews all assessing the effects 
of alpha-2-agonists. None found evidence of a reduction 
of mortality (systematic review RR 0.99, 95% CI 0.79 to 
1.24). The systematic review and three semisystematic 
reviews found no evidence of an effect for the prevention 
of delirium (systematic review RR 0.85, 0.63 to 1.14). 
Conversely, four semisystematic reviews found a beneficial 
effect. Serious adverse events, quality of life, non-serious 
adverse events and cognitive function were not assessed. 
We did not identify any systematic or semisystematic 
reviews addressing other pharmacological interventions 
for the prevention of delirium. For the management of 
manifest delirium, we did not identify any systematic or 
semisystematic review assessing any pharmacological 
agents.
Conclusion Based on systematic reviews, the evidence 
for the use of pharmacological interventions for 
prevention or management of delirium is poor or sparse. 
A systematic review with low risk of bias assessing the 
effects of pharmacological prevention of delirium and 
management of manifest delirium in ICU patients is 
urgently needed.
PrOsPErO registration number CRD42016046628. 
IntrOduCtIOn 
Delirium is a complex acute organic 
syndrome characterised by a reduced ability 
to focus, sustain or shift attention, and either 
a change in cognition or the development 
of perceptual disturbances.1 Delirium is 
classified in motoric subtypes: (1) hypoac-
tive delirium; (2) hyperactive delirium and 
(3) a mixed form delirium. Hypoactive and 
mixed delirium are most common in inten-
sive care unit (ICU) patients,2 3 and hypo-
active delirium has been suggested to have 
worse outcomes.4 In ICU patients, 25% to 
89% are reported to be affected by delirium, 
which is associated with increased mortality 
in these patients.5–9 Furthermore, delirium 
is associated with increased morbidity, 
including increased duration of mechanical 
ventilation, and ICU and hospital length of 
stay.6 10–16 Patients with delirium may experi-
ence functional decline after ICU discharge 
and long-term cognitive impairment.11 12 15 
Up-to-date critical care guidelines recom-
mend non-pharmacological strategies in 
both the prevention and management of 
manifest delirium.17 These strategies may 
include early mobilisation and reorientation 
strengths and limitations of this study
 ► We used a transparent and systematic method 
which followed widely accepted methodological 
standards.
 ► We conducted a thorough and comprehensive liter-
ature search.
 ► Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses was chosen as the gold stan-
dard for defining a systematic review.
 ► We did not search for individual trials or performed 
meta-analyses and Trial Sequential Analysis within 
each of the groups of pharmacological agents.
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of the patient, risk factor assessment and normalisation 
of the sleep–wake cycle.18 When delirium is suspected 
or identified, guidelines suggest that patients should 
be evaluated to identify potential underlying causes, 
allowing for deficiencies to be corrected, or exposures to 
be removed. Only when non-drug methods have failed to 
control symptoms should pharmacological interventions 
be used.19 20 Nonetheless, a recently performed inception 
cohort study found that haloperidol was used as manage-
ment option in 46% of ICU patients diagnosed with 
delirium, and dexmedetomidine in 21%.16
Pharmacological interventions for delirium have 
focused on alterations in neurotransmitter pathways, 
in particular dopaminergic and cholinergic pathways. 
Several pharmacological strategies have been used 
against delirium in the ICU patients: antipsychotics; seda-
tives; cholinesterase inhibitors; opioids; and melatonin 
and melatonin antagonists. Haloperidol is considered 
the drug of choice when managing manifest delirium 
in ICU settings21–25 and some international guidelines 
recommend haloperidol in the management of manifest 
ICU delirium.19 26 27 However, the two latest iterations of 
the guideline by the American College of Critical Care 
Medicine and the Society of Critical Care Medicine no 
longer recommend managing delirium with haloperidol 
due to lack of evidence.17 28 In general, pharmacological 
interventions are not recommended for the prevention 
of delirium in ICU patients.19 26–28
Systematic reviews and meta-analyses have become 
one of the most widely used methods to quantify the 
effects of medical interventions and are frequently being 
recognised as the best available evidence for decisions 
about healthcare management and policy.29 30 A prelim-
inary search identified several reviews investigating the 
effects of pharmacological interventions for the preven-
tion and management of delirium. However, uncertainty 
regarding the benefits and harms of pharmacological 
interventions appeared to be considerable, and trials 
have shown either positive,31 32 equipoise33 34 or negative 
results.35
The objective of this overview of reviews was to system-
atically and critically assess the quantity and the quality 
of the available reviews and meta-analyses of randomised 
clinical trials on the effects of pharmacological preven-
tion and management of delirium in ICU patients.
MEthOds
We conducted this systematic overview of reviews 
with a registered (PROSPERO CRD42016046628) 
and published protocol,36 in accordance with the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) (Electronic supplementary 
material (ESM), table 1). We used the systematic review 
methods principles outlined in the Cochrane Hand-
book37 and the recommendations given by Robinson 
et al.38
Criteria for considering reviews for inclusion
We included all reviews and meta-analyses of pharmaco-
logical interventions for the prevention of delirium or 
management of manifest delirium (defined as diagnosed 
delirium) in adult ICU patients. We predefined a system-
atic review as a review positively fulfilling the PRISMA 
reporting guidelines.39
We defined adult ICU patients as those treated in an 
ICU (or similar terms defined by the review authors) 
of any specialty, for example, medical, surgical, trauma, 
cardiac. We included reviews of ICU patients aged 18 
years or older and included both acute surgery patients 
and elective cardiac surgery patients.
Table 1 Summary of risk of bias assessment of the single systematic review and the eight semisystematic reviews using 
ROBIS
Review
Violated 
PRISMA 
criteria
ROBIS Phase 2 ROBIS Phase 3
Study eligibility 
criteria
Identification and 
selection of studies
Data collection and 
study appraisal
Synthesis 
and findings
Overall risk of 
bias in the review
Tan et al53 #4; #5     
Lin et al51 #5; #27     
Fraser52 #5; #8     
Xia et al47 #5     
Zhang et al48 #5     
Pasin et al50 #5; #27     
Chen et al46 0     
Tran et al54 #15; #22     
Liu et al49 #5     
#4, objectives; #5, protocol and registration; #8, search; 15, risk of bias across studies (methods); #22, risk of bias across studies (results); 
#27, funding;  , low risk; , high risk.
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We excluded reviews on ICU patients with delirium 
caused by alcohol withdrawal, terminally ill patients, 
patients admitted to emergency departments and elective 
surgery patients, except cardiac surgery.
Results on all primary and secondary outcomes of 
the included systematic reviews were a priori planned 
to be reported.36 However, we defined the primary 
and secondary outcomes in this overview of reviews as 
follows36:
Primary outcomes
1. All-cause mortality
2. Proportion of participants with a serious adverse event, 
defined as an event (experience) or reaction in any 
untoward medical occurrence that at any dose results 
in death, is life-threatening, requires prolongation of 
hospitalisation or results in persistent or significant dis-
ability/incapacity40
3. Proportion of participants with resolution of delirium 
symptom at end of treatment (management of deliri-
um) and proportion of participants with delirium de-
spite the administration of a pharmacological agent 
before being diagnosed with delirium (prevention of 
delirium)
Secondary outcomes
1. Quality of life as defined by review authors (eg, mea-
sured with SF36)41
2. Proportion of participants with non-serious adverse 
events defined as adverse events which are not serious
3. Cognitive function as defined by review authors (eg, 
measured with Repeatable Battery for the Assessment 
of Neuropsychological Status)42 (continuous score)
search methods for identification of reviews
We searched the Cochrane Library, MEDLINE (OvidSP), 
Embase (OvidSP), Science Citation Index-Expanded 
(Web of Science), BIOSIS Previews (Web of Science), 
Cumulative Index to Nursing & Allied Health Literature 
(CINAHL), Latin American Caribbean Health Sciences 
Literature (LILACS) and Allied and Complementary 
Medicine Database (AMED) in July 2017, in order to 
identify reviews eligible for inclusion. Full search strate-
gies and time spans of the searches are provided in elec-
tronic  supplementary material—ESM.
data collection and analysis
Four authors (MB, SRK, MOC, LKL) independently 
screened the titles and abstracts of all reports identified in 
the searches using Covidence and comparison was made 
within pairs.43 Reports deemed potentially relevant by any 
of the review authors were obtained in full text, and the 
full-text papers were assessed for eligibility by two review 
authors independently before being assessed for inclusion 
and compared within pairs. Disagreements were resolved 
by consensus. Reviews containing a methods section and/
or a literature search were hereafter checked against 
the PRISMA criteria.39 Initially, it was our intention to 
only include systematic reviews fulfilling all 27 PRISMA 
criteria, but we decided pragmatically to define a group 
of reviews which failed on a maximum of two arbitrary 
PRISMA criteria as semisystematic reviews.
Four authors (MB, SRK, MOC, LKL) independently 
extracted predefined data of the included reviews using 
a data extraction form (supplementary material), which 
was specifically designed and piloted by the review team, 
and comparisons were made in pairs.
We extracted the following review characteristics:
1. Review identification: authors, year, title
2. From the systematic review(s), we extracted data on the 
number of trials included, the number of participants 
included, ICU population (eg, medical or surgical), di-
agnostic criteria of delirium, type of pharmacological 
agent(s) included, primary and secondary outcomes, 
results on primary and secondary outcomes, type of 
meta-analytic and sequential analysis used and the au-
thors’ conclusion
In addition, for all included reviews and meta-anal-
yses, we extracted information on whether haloperidol 
was recommended for the management of delirium 
registered as either ‘Yes/No/Not stated’. Disagreements 
concerning the extracted data were discussed and deci-
sion reached between the authors.
Assessment of methodological quality of included reviews
The methodological quality of the reviews failing on a 
maximum of two arbitrary PRISMA criteria were here-
after assessed with the ROBIS tool.44
data synthesis
We a priori36 planned to perform meta-analysis and trial 
sequential analysis45 of the trials with overall low risk of 
bias. However, as we solely identified trials with overall 
high risk of bias, we did not perform the analyses.
We categorised reviews into:
1. Systematic reviews (a review positively fulfilling all 27 
PRISMA criteria)39
2. Semisystematic reviews being in overall agreement 
with the PRISMA statement except failing on a maxi-
mum of two arbitrary PRISMA criteria
3. Narrative reviews (any review not fulfilling the criteria 
for a systematic review or the criteria for a semisystem-
atic review)
For the systematic reviews assessed to be of low risk of 
bias, two authors (MB, MOC) independently assessed 
the methodological quality of each included trial with 
the Cochrane risk of bias tool.37 Disagreements were 
discussed, and agreement was reached between the 
authors. Results are presented narratively by the indica-
tion for use (prevention or/and management), followed 
by the type of pharmacological agent and the type of 
outcome.
PAtIEnts And PublIC InvOlvEMEnt
Patients and the public were not involved in this research.
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rEsults
We identified 5036 potentially relevant references and 
finally included 378 reviews (figure 1).
description of included reviews
We only identified one systematic review46 fulfilling all 
27 PRISMA criteria (ESM table 2), eight semisystematic 
reviews47–54 failing on a maximum of two PRISMA criteria 
and 369 narrative reviews.
The systematic review
 ► Chen et al46 assessed the safety and efficacy of alpha-2 
agonists for sedation, compared with traditional seda-
tives, in mechanically ventilated critically ill patients. 
This review included seven trials randomising 1624 
participants. All included trials investigated adults 
and compared dexmedetomidine with traditional 
sedatives (propofol, midazolam or lorazepam).
Semisystematic reviews
1. Tan et al53 assessed the effects of using dexmedetomi-
dine as a sedative and analgesic agent compared with 
placebo or alternative sedative agents, such as propofol 
and benzodiazepines, in critically ill patients; 24 ran-
domised trials, involving 2419 patients, were included.
2. Lin et al51 assessed the effects of using dexmedetomi-
dine compared with alternative sedative agents fol-
lowing cardiac surgery; five randomised trials and six 
observational studies were included. We report on a 
subgroup analysis including five randomised trials and 
a prospective descriptive study.
3. Fraser et al52 reviewed benzodiazepine compared with 
non-benzodiazepine (four randomised trials with dex-
medetomidine and two with propofol) regimens in 
mechanically ventilated ICU patients. Six randomised 
trials, involving 1225 patients, were included.
4. Xia et al47 assessed the influence of dexmedetomidine 
and propofol on adult ICU sedation. Ten randomised 
trials, involving 1202 participants, were included.
5. Zhang et al48 included all postoperative trials reporting 
on delirium risk. We report on only one comparison, 
alpha-2-adrenoreceptor agonists compared with other 
sedatives for the risk of postoperative delirium, where 
only cardiac surgical trials have been included, as the 
other outcomes included patient groups we excluded 
(two randomised trials on dexmedetomidine and one 
on clonidine, involving 445 patients).
6. Pasin et al50 compared dexmedetomidine with any 
comparator in the ICU setting (nine randomised tri-
als in ICU, four in cardiac surgery and one in cervical 
spine surgery, including a total of 3029 patients).
7. Tran et al54 assessed alpha-2 agonists (all trials re-
ported on dexmedetomidine) for non-procedur-
al sedation in critically ill brain-injured patients on 
mechanical ventilation. Both randomised trials and 
observational studies were included. Six randomised 
trials including a total of 318 patients were included. 
However, due to lack of clinical homogeneity of the 
randomised trials and studies, pooling was deemed 
inappropriate. We only report on outcomes which 
were defined a priori.
8. Liu et al49 compared the effects of dexmedetomidine 
and propofol sedation in adult patients after cardiac 
surgery; eight randomised trials involving 969 patients 
were included.
risk of bias in the systematic review and the eight 
semisystematic reviews
We assessed the systematic review by Chen et al46 as overall 
low risk of bias (table 1).
However, the seven included trials55–60 were all overall 
high risk of bias (figure 2). The eight semisystematic 
reviews failing on a maximum of two arbitrary PRISMA 
criteria, by Tan et al,53 Lin et al,51 Fraser et al,52 Xia et al,47 
Zhang et al,48 Pasin,50 Tran54 and Liu et al,49 were all overall 
high risk of bias. All 46 trials included in these eight semi-
systematic reviews were overall high risk of bias.
Effects of pharmacological interventions for delirium in ICu 
patients
Prevention of delirium
Antipsychotics
We did not identify any systematic review or semisystem-
atic review assessing the effects of antipsychotics (eg, 
haloperidol) for the prevention of delirium.
Figure 1 Preferred reporting items for systematic reviews 
and meta-analyses flowchart.
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Sedatives
All-cause mortality
When assessing mortality (table 2), Chen et al46 did 
not find evidence for a difference when comparing 
dexmedetomidine with traditional sedatives (midazolam, 
lorazepam or propofol).
Neither did Tan et al53 and Lin et al51 when comparing 
dexmedetomidine with traditional sedatives. Additionally, 
Table 2 Pooled effect estimates reported by the systematic review and semisystematic reviews by outcome and type of 
pharmacological agent
Antipsychotics Sedatives (dexmedetomidine)
Cholinesterase 
inhibitors Opioids Melatonine
Primary outcome
All-cause mortality -* –* –* –*
  Chen –* RR 0.99, 0.79 to 1.24; 6 randomised trials 
including 1584 patients
–* –* –* 
  Tan –* RR 0.85, 0.64 to 1.13; 16 randomised trials 
including 1839 patients
–* –* –* 
  Lin –* RR 1.00, 0.28 to 3.60, 3 randomised trials 
including 444 patients
–* –* –* 
  Xia –* RR 0.83, 0.32 to 2.12; 5 randomised trials 
including 267 patients
–* –* –* 
  Fraser –* RR 1.01, 0.78 to 1.30; 4 randomised trials 
including 1101 patients
–* –* –* 
Serious adverse 
events
–* –* –* –* –*
Delirium prevention –* –* –* –*
  Chen –* RR 0.85; 0.63 to 1.14; 7 randomised trials 
including 1624 patients
–* –* –* 
  Tan –* RR 0.79, 0.56 to 1.11; 8 randomised trials 
including 1754 patients
–* –* –* 
  Fraser –* RR 0.82, 0.61 to 1.11; 2 randomised trials 
including 469 patients
–* –* –* 
  Zhang –* RR 0.55, 0.23 to 1.28; 3 randomised trials 
including 445 patients†
–* –* –* 
  Lin –* RR 0.35, 0.19 to 0.63; 3 randomised trials 
including 478 patients
–* –* –* 
  Xia –* RR 0.40, 0.22 to 0.74; 3 randomised trials 
including 658 patients
–* –* –* 
  Liu –* RR 0.40, 0.24 to 0.64; 4 randomised trials 
including 393 patients
–* –* –* 
  Pasin –* RR 0.68, 0.49 to 0.96; 14 randomised trials 
including 3029 patients
–* –* –* 
  Tran –* Meta-analysis not performed, 0 trials included 
on this outcome
–* –* –* 
Delirium 
management
-* -* -* -* -*
Secondary outcomes
Quality of life –* –* –* –* –*
Non-serious adverse 
events
–* –* –* –*
  Tran –* Meta-analysis not performed, 3 included trials 
was described narratively
–* –* –* 
Cognitive function –* –* –* –*
*No systematic review or semisystematic review identified or assessed this outcome.
†Clonidine and dexmedetomidine.
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Xia et al47 compared dexmedetomidine with propofol 
and also found no difference in mortality. Fraser et al52 
compared benzodiazepines with non-benzodiazepines 
(dexmedetomidine or propofol) and found no differ-
ence in mortality.
 
Serious adverse events
We did not identify any systematic review or semisystem-
atic review assessing the effects of sedatives on risk of 
serious adverse events.
 
Risk of delirium
When assessing the effect of prophylactic use of alpha-2-ag-
onists compared with alternative sedatives on the subse-
quent risk of delirium (table 2), the systematic review (on 
dexmedetomidine)46 and three semisystematic reviews 
(two assessing dexmedetomidine52 53 and one overall 
alpha-2-agonists48) did not find evidence of an effect.
Conversely, four semisystematic reviews47–51 and a 
subgroup analysis (including two trials and a total of 
415 patients) in a semisystematic review, which assessed 
alpha-2-agonists in the primary analysis,48 found evidence 
of a beneficial effect of dexmedetomidine compared with 
different alternative sedatives.47–51 In various subgroup 
analyses (on patients undergoing invasive ventilation, 
compared with midazolam only, restricted to general 
ICU), without any adjustment for statistical multiplicity, 
dexmedetomidine was found to have a beneficial effect 
for the prevention of delirium.50
Quality of life
We did not identify any systematic review or semisystem-
atic review assessing quality of life.
 
Proportion of participants with non-serious adverse 
events
When assessing adverse events, Tran et al54 narratively 
reported on three trials. Two trials found no evidence of 
a difference in adverse events comparing dexmedetomi-
dine with propofol, or between dexmedetomidine and 
midazolam.61 62 The third trial comparing dexmedeto-
midine with normal saline found that dexmedetomidine 
was associated with higher rates of bradycardia, but with 
lower rates of tachycardia.63
 
Cognitive function
We did not identify any systematic review or semisystem-
atic review assessing cognitive function.
 
Additional outcomes reported by the systematic review 
and the semisystematic reviews
Twenty-three additional outcomes (mainly) on the effect of 
dexmedetomidine versus other sedatives were reported by 
the systematic review and semisystematic reviews (supplemen-
tary material table 3).
Cholinesterase inhibitors
We did not identify any systematic review or semisystem-
atic review assessing the effects of cholinesterase inhibi-
tors for the prevention of delirium.
Opioids
We did not identify any systematic review or semisystem-
atic review assessing the effects of opioids for the preven-
tion of delirium.
Melatonine and melatonine inhibitors
We did not identify any systematic review or semisystem-
atic review assessing the effects of melatonine or mela-
tonine inhibitors for the prevention of delirium.
Management of delirium
Antipsychotics
We did not identify any systematic review or semisystematic 
review assessing the effects of antipsychotics (eg, haloperidol) 
for the management of manifest delirium (table 2).
Of all 378 included reviews, 227 (60%) stated that halo-
peridol was indicated for the management of delirium, 43 
(11%) stated that haloperidol was contraindicated and 108 
(29%) did not state whether haloperidol was indicated or 
not.
Figure 2 Risk of bias summary: review authors’ judgements 
about each risk of bias item for each included trial in the only 
included systematic review (Chen 2015).
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Sedatives
We did not identify any systematic review or semisys-
tematic review assessing the effects of sedatives for the 
management of manifest delirium.
Cholinesterase inhibitors
We did not identify any systematic review or semisystem-
atic review assessing the effects of cholinesterase inhibi-
tors for the management of manifest delirium.
Opioids
We did not identify any systematic review or semisystem-
atic review assessing the effects of opioids for the manage-
ment of manifest delirium.
Melatonine and melatonine inhibitors
We did not identify any systematic review or semisystematic 
review assessing the effects of melatonine or melatonine 
inhibitors for the management of manifest delirium.
dIsCussIOn
summary of main results
This overview addresses the evidence for the prevention 
of delirium and management of manifest delirium with 
pharmacological agents in ICU patients. We identified 
only one systematic review46 out of a total of 378 reviews 
which addressed this topic. We classified eight as semisys-
tematic reviews47–53 and 369 as narrative reviews. We only 
found the systematic review to have overall low risk of 
bias; all eight semisystematic reviews had overall high risk 
of bias. The identified systematic review with low risk of 
bias included seven randomised clinical trials55–60; which 
all had overall high risk of bias. Our main results are 
summarised in the Summary of findings table (table 3).
strengths and limitations of this study
This overview of reviews has several methodological 
strengths. We conducted a comprehensive literature 
search to identify reviews and meta-analyses in six major 
electronic databases, with specifically designed search 
strategies with no limits to publication year, type of publi-
cation or language. We used a transparent and systematic 
method, which was registered and published before the 
initiation of this project. Each phase of the screening, 
data extraction, data collection and methodological eval-
uations were performed by independent review authors 
working in pairs.
This overview of reviews also has methodological 
limitations. First, we chose PRISMA as the gold standard 
for defining a systematic review. One may argue that it is 
difficult for older reviews to adhere to the PRISMA state-
ment, as this was published in 2009. One may also argue 
that there may be PRISMA criteria that might not be as 
important as others, for example, a structured abstract. 
In contrast, risk of bias evaluation in individual trials is 
of huge importance for the conclusion of the review.64 
Therefore, we chose pragmatically to classify all reviews, 
failing on a maximum of two PRISMA criteria, as semisys-
tematic reviews. Second, we did not search for individual 
trials to perform a systematic review with meta-anal-
yses and trial sequential analysis within each of the 
groups of pharmacological agents. Unfortunately, our 
results revealed that no systematic review on delirium 
management with any pharmacological agent has been 
published. Thus, we cannot discuss the evidence on 
pharmacological prevention or management strategies 
based on published trials, but merely according to the 
published reviews.
Table 3 Summary of findings
Pharmacological 
intervention
No. of systematic 
reviews according 
to PRISMA with 
low risk of bias
No. of systematic 
reviews 
according to 
PRISMA with 
high risk of bias
No. of 
semisystematic 
reviews 
according to 
PRISMA*
Quality of 
the evidence Comments
Delirium 
prevention
1 0 8 low Seven trials with overall 
high risk of bias included in 
the systematic review with 
low risk of bias. The eight 
semisystematic reviews were all 
high risk of bias and included 
solely trials with overall high 
risk of bias.
Delirium 
management
0 0 0 No evidence No systematic reviews 
according to PRISMA were 
identified. Neither was a 
semisystematic review 
identified.
Presence and quality of evidence by type of pharmacological intervention.
*In agreement with the PRISMA statement except two arbitrary PRISMA criteria.
PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
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Current research within delirium is challenged by meth-
odological and clinical limitations. The main limitations 
revealed by this overview of reviews is the overall high 
risk of bias found both in all the semisystematic reviews 
and all the included trials. It is therefore likely that we 
purport results that are also biased, that is, beneficial 
results may be overestimated, and harms may be underes-
timated.64–66 In addition, we found a significant limitation 
to the research in the ICU delirium field, as systematic 
reviews adhering (or largely) to the PRISMA criteria all 
examined dexmedetomidine, which therefore domi-
nates the current literature on pharmacological agents 
for delirium. Furthermore, the mechanisms of delirium 
are still not fully established and the underlying cause of 
delirium in medical ICU patients may be different from 
those in postoperative ICU patients, suggesting different 
optimal prevention and management strategies in the 
mixed ICU population. Certain subgroups of patients 
with delirium and risk factors at baseline (eg, age, severity 
of illness, exposure to a surgical procedure, cognitive 
dysfunction) may influence patient-centred outcomes 
differently. Current published trials have not stratified 
according to these factors but may in future research 
add new knowledge to the ICU field. Another important 
consideration is that many so-called placebo-controlled 
trials are not truly placebo-controlled, as some trials 
include rescue medications like haloperidol ‘as needed’.
No study has previously attempted to systematically 
collect and evaluate all published reviews within phar-
macological interventions for delirium. We found that 
narrative and non-systematic reviews dominate the litera-
ture on pharmacological interventions for delirium. Our 
findings confirm the observations by Siontis et al67 that 
publications of erratic quality are produced in massive 
scales, in publications on the same topic, making it diffi-
cult to quickly get an evidence-based insight and over-
view. Our results reveal that many reviews cite trial results 
uncritically, leaving readers with the impression that, for 
example, haloperidol is a proven suitable pharmaco-
logical agent for the management of manifest delirium. 
Rapid access to current research to ensure evidence-based 
decision making and practice is increasingly demanded 
by the healthcare system, but guideline developers and 
decision makers are likely to be overwhelmed by the high 
numbers of published reviews of erratic quality.
delirium prevention
Using a pharmacological delirium prevention protocol 
in adult ICU patients is not currently recommended.17 
The identified systematic review and eight semisystem-
atic reviews considered prevention of delirium with 
dexmedetomidine, when used as a sedative, and found 
conflicting results, five in favour of dexmedetomidine47–51 
and three showing equipoise46 52 53 results. However, trials 
with overall high risk of bias and small sample sizes not 
reaching the required information size in a meta-anal-
ysis,68 as well as demonstrating huge heterogeneity of 
unexplained origin, prevent us from presenting any 
recommendations for the use of dexmedetomidine 
for the prevention of ICU delirium. We did not find a 
systematic review or semisystematic review addressing 
delirium prevention with haloperidol. To our knowledge, 
10 randomised trials on haloperidol including a total of 
3772 ICU patients or patients having major surgeries have 
been published.32–34 69–75
Sedation trials for the prevention of delirium over-
shadows research in preventive strategies. However, 
today, sedation is generally lessened, and light seda-
tion and daily sedative interruption are recommended 
(low-quality evidence).17 Sedation with dexmedetomidine 
and propofol are recommended over benzodiazepines in 
mechanically ventilated adults (low quality of evidence)17; 
however, no pharmacological agent is recommended for 
the prevention of delirium.17 Patients may presumably 
benefit from being sedated with an agent which may 
lower the incidence of delirium, but using an agent to 
prevent delirium may then compete with the trend of 
minimising sedation.76
delirium management
We did not find a systematic review according to the 
PRISMA criteria addressing pharmacological agents for 
the management of manifest delirium in ICU patients. 
To our knowledge, seven randomised trials investi-
gating the effect of haloperidol for the management 
of manifest delirium in critically ill patients have been 
published35 77–82 including only a total of 394 critically ill 
patients. Our overview of reviews demonstrates that the 
majority of reviews (60%), discussing the effect or use of 
haloperidol for delirium management, cite that haloper-
idol is indicated, and only 11% states that haloperidol is 
contraindicated. For whatever reason, the widespread use 
and endorsement of haloperidol contradicts the frequent 
serious adverse reactions shown in other settings,28 and 
the fact that the Food and Drug Administration warns 
against the use of haloperidol in patients with demen-
tia-related psychosis, because of a 1.6-times increased 
mortality.83
unanswered questions and future research
In evidence-based medicine, systematic reviews of 
randomised trials rank highest. However, systematic 
reviews must be performed based on methods aiming to 
minimise systematic and random errors; otherwise, the 
results will be questionable. In addition to a thorough 
and systematic bias risk assessment, meta-analysis needs to 
reach a required information size (meta-analytic sample 
size) based on a minimal important clinical difference to 
conclude whether an intervention is better than another. 
Otherwise, a conclusion based on meta-analyses with high 
risk of random error45 65 84 may be communicated. The 
lack of evidence and poor quality of the present evidence 
on the use of pharmacological agents for delirium leave 
clinicians to decide which pharmacological intervention 
to use. Research on how to deal with the management 
of manifest delirium, when all non-pharmacological 
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options have been used, is highly warranted. Although 
multicomponent, non-pharmacological intervention 
focusing on reducing modifiable risk factors for delirium, 
improving cognition and optimising sleep, mobility, 
hearing, and vision in critically ill adults, as well as 
early mobilisation, is recommended to reduce the inci-
dence and duration in the ICU, this is only supported 
by low quality of evidence.17 In settings outside the ICU, 
non-pharmacological multicomponent protocols have 
shown promising results (moderate level of quality).85 86 
However, such multifaceted interventions have not been 
adequately studied in the ICU setting. Based on the avail-
able evidence, one might get the idea that there is some 
evidence for the effect of dexmedetomidine to prevent 
delirium. However, as our overview underlines, there is 
really no valid evidence to support the use of dexmede-
tomidine and none at all that dexmedetomidine is better 
than haloperidol (or vice versa), which seems to be the 
preferred agent so far.16 19
COnClusIOn
Our overview of reviews demonstrated that systematic 
reviews and semisystematic reviews currently available in 
the delirium literature are heterogeneous in quality with 
high risk of bias. The results were conflicting regarding 
the effect of dexmedetomidine for the prevention of 
delirium based on the high-quality systematic review and 
the semisystemtic reviews. There is no evidence for the 
use of any pharmacological agent for the management of 
manifest delirium based on systematic or semisystematic 
reviews. 
There is an urgent need for a systematic review with low 
risk of bias assessing the effects of pharmacological preven-
tion of delirium and management of manifest delirium in 
ICU patients. Especially the effects of haloperidol need 
to be assessed, because haloperidol is the most recom-
mended drug for the management of delirium. Future 
systematic reviews should aim to adhere to the PRISMA 
statement, so risk of systematic errors is minimised, and 
the best available evidence is presented. Furthermore, 
future trials on any antidelirious agent should report on 
patient-centred outcomes.
Identifying the most effective intervention for both 
the prevention of delirium and management of manifest 
delirium in ICU patients will benefit patients, relatives 
and healthcare systems around the world.
difference between protocol and review
In our published protocol which was written a priori initi-
ation of the overview, we stated that we would categorise 
reviews into the following groups: (1) systematic reviews 
according to PRISMA with low risk of bias assessed with 
ROBIS; (2) systematic reviews according to PRISMA with 
high risk of bias assessed with ROBIS; and (3) non-system-
atic reviews according to PRISMA.
Because we only found one systematic review fulfilling 
all the PRISMA criteria, we decided post protocol 
publication to acknowledge reviews almost fulfilling the 
PRISMA criteria by adding the category semisystematic 
reviews.
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